Journal Mobile Options
Table of Contents
Vol. 145, No. 3, 2008
Issue release date: February 2008
Int Arch Allergy Immunol 2008;145:224–230

Date Palm Pollen Allergoid: Characterization of Its Chemical-Physical and Immunological Properties

Mistrello G. · Harfi H. · Roncarolo D. · Kwaasi A. · Zanoni D. · Falagiani P. · Panzani R.
aLofarma S.p.A., Milan, Italy; bNational Center of Allergy, Asthma and Immunology, Riyad, and cKing Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; dUniversity of Oxford, Botnar Research Centre, Oxford, UK; eCentre de Recherche en Allergologie, Marseille, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Date palm (DP) pollen can cause allergic symptoms in people living in different countries. Specific immunotherapy with allergenic extracts by subcutaneous route is effective to cure allergic people. However, the risk of side effects has led to explore safer therapeutic modalities. The aim of our work was to evaluate IgE cross-reactivity between DP and autochthonous palm (European fan palm, EFP) pollen extracts, to chemically modify DP extract with potassium cyanate in order to obtain an allergoid, and to characterize it. Methods: By radioallergosorbent test inhibition, immunoblotting (IB) and skin prick test, in vitro and in vivo allergenic activities of native and modified DP extracts were compared. By SDS-PAGE and IB, we compared the protein profile and IgE-binding capacity of both native and modified DP, as well as of EFP extracts. By IB inhibition, IgE cross-reactivity of native DP and EFP extracts was evaluated. By ELISA, the capacity of modified DP-induced IgG to react with native DP extract was determined. Results: Radioallergosorbent test inhibition, IB and skin prick test results demonstrated that modified DP was significantly less allergenic than native DP extract. The SDS-PAGE profile showed that potassium cyanate treatment of DP extract did not alter the molecular weight of its components. In addition, no difference was observed between native DP and EFP extracts. Subsequent IB inhibition data evidenced the existence of a strong IgE cross-reactivity between native DP and EFP extracts. ELISA results indicated that the administration of modified DP in mice was able to induce specific IgG also recognizing native DP extract. Conclusions: Modified DP extract (allergoid) seems to be a good candidate for immunotherapy of patients affected by specific allergy.

 goto top of outline Author Contacts

Correspondence to: Dr. Gianni Mistrello
Lofarma S.p.A.
Viale Cassala 40
IT–20143 Milan (Italy)
Tel. +39 02 5819 8225, Fax +39 02 5819 8302, E-Mail

 goto top of outline Article Information

Received: November 13, 2006
Accepted after revision: June 18, 2007
Published online: October 3, 2007
Number of Print Pages : 7
Number of Figures : 4, Number of Tables : 0, Number of References : 44

 goto top of outline Publication Details

International Archives of Allergy and Immunology

Vol. 145, No. 3, Year 2008 (Cover Date: February 2008)

Journal Editor: Valenta, R. (Vienna)
ISSN: 1018–2438 (Print), eISSN: 1423–0097 (Online)

For additional information:

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kwaasi AAA, Tipirneni P, Harfi H, Parhar R, Al-Sedairy ST: Date palm (Phoenix dactylifera L) pollen is a potent allergen. Ann Allergy 1992;68:78.
  2. Fernandez J: Allergenic activity of date palm (Phoenix dactylifera) pollen. Allergy 1992;47:78.
  3. Kwaasi AAA, Parhar RS, Tipirneni P, Harfi H, Al-Sedairy ST: Characterisation of antigens and allergens of date palm (Phoenix dactylifera L) pollen: immunological assessment of atopic patients using whole extract or its fractions. Allergy 1992;47:535–544.
  4. Waisel Y, Kenyan N, Gil T, Tatar D, Bezerano A, Goldberg A, Geller-Bernstein C, Dolev Z, Tamir R, Levy I, et al: Allergic responses to date palm and pecan pollen. Harefuah 1994;126:305–310.
  5. Kosman E, Eshel A, Kenyan N, Waisel Y: Clustering of allergenic pollen on the basis of skin responses of atopic patients by matrix analysis. Allergy 1994;49:502–507.
  6. Gonzalo MA, Moneo I, Ventas P, Polo F, Garcia JM: Immediate hypersensitivity reaction to date. Allergy 1997;52:598–599.
  7. Ezeamuzie CI, Al-Mousawi M, Dashti H, Al-Bashir A, Al-Hage M, Al-Ali S: Prevalence of allergic sensitisation to inhalant allergens among blood donors in Kuwait – a desert country. Allergy 1997;52:1194–1200.
  8. Chowdhury I, Chakraborty P, Gupta-Bhattacharya S, Chanda S: Allergenic relationship among four common and dominant airborne palm pollen grains from Eastern India. Clin Exp Allergy 1998;28:977–983.
  9. Chakraborty P, Chowdhury I, Gupta-Bhattacharya S, Gupta S, Sengupta DN, Chanda S: Clinicoimmunologic studies on Phoenix sylvestris Roxb pollen: an aeroallergen from Calcutta, India. Allergy 1999;54:985–989.
  10. Bener A, Safa W, Abdulhalik S, Lestringant GG: An analysis of skin prick test reactions in asthmatics in a hot climate and desert environment. Allerg Immunol (Paris) 2002;34:281–286.
  11. Raffard M, Guinnepain MT: Un cas d’asthme au pollen de dattier. Rev Fr Allergol Immunol Clin 2001;41:9.
  12. Kwaasi AAA, Parhar RS, Tipirneni P, Harfi HA, Al-Sedairy ST: Cultivar-specific epitopes in date palm (Phoenix dactylifera L) pollenosis: differential antigenic and allergenic properties of pollen from ten cultivars. Int Arch Allergy Immunol 1994;104:281–290.
  13. Kosman E, Eshel A, Waisel Y: The ‘traveling salesman problem’: a new approach for identification of differences among pollen allergens. Int Arch Allergy Immunol 1997;112:371–377.
  14. Kwaasi AAA, Harfi HA, Parhar RS, Collison KS, Al-Sedairy ST, Al-Mohanna FA: Cultivar-specific IgE-epitopes in date (Phoenix dactylifera L) fruit allergy. Correlation of skin test reactivity and IgE-binding properties in selecting date cultivars for allergen standardization. Int Arch Allergy Immunol 2000;123:137–144.
  15. Kwaasi AAA: Date palm and sandstorm borne allergens. Clin Exp Allergy 2003;4:419–426.

    External Resources

  16. Kwaasi AAA, Parhar RS, Tipirneni P, Harfi H, Al-Sedairy ST: Major allergens of the date palm (Phoenix dactylifera L) pollen: identification of IgE binding components by ELISA and immunoblot analysis. Allergy 1993;48:511–518.
  17. Fernandez J, Asturias JA, Martinez A: Biological standardisation and allergen characterisation of date palm pollen (Phoenix dactylifera). Allergy 2000;55:140.
  18. Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P: Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 1996;51:8–15.
  19. Bacal E, Zeiss CR, Suszko I, Levitz D, Patterson R: Polymerized whole ragweed: an improved method of immunotherapy. J Allergy Clin Immunol 1978;62:288–294.
  20. Patterson R, Suszko IM, Bacal E, Zeiss CR, Kelly JF, Pruzansky JJ: Reduced allergenicity of high molecular weight ragweed polymers. J Allergy Clin Immunol 1979;63:47–50.
  21. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
  22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with Folin phenol reagent. Biol Chem 1970;193:265–275.
  23. Ceska M, Eriksson R, Varga JM: Radio-immunosorbent assay of allergens. J Allergy Clin Immunol 1975;49:1.

    External Resources

  24. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350–4354.
  25. Asturias JA, Ibarrola I, Fernandez J, Arilla MC, Gonzalez-Rioja R, Martinez A: Pho d 2, a major allergen from date palm pollen, is a profilin: cloning, sequencing, and immunoglobulin E cross-reactivity with other profilins. Clin Exp Allergy 2005;35:374–381.
  26. Tal M, Silberstein A, Nusser E: Why does Coomassie Brilliant Blue R interact differently with different proteins? A partial answer. J Biol Chem 1985;260:9976–9980.
  27. Abramson MJ, Puy RM, Weiner JM: Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003:CD001186.
  28. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities from immunotherapy (IT) and skin testing. J Allergy Clin Immunol 1987;79:660–677.
  29. Ariano R, Panzani RC, Augeri G: Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen. A double-blind study. Invest Allergol Clin Immunol 1998;8:155–160.
  30. Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW, Passalacqua G: Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy 2001;56:989–992.
  31. Gamberi E, Arena A, D’Anneo R, La Grutta S: Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol 2005;33:142–144.
  32. Rossi RE, Monasterolo G: A pilot study of feasibility of ultra-rush (20–25 minutes) sublingual-swallow immunotherapy in 679 (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005;18:277–285.
  33. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, Canonica GW: Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629–632.
  34. Caffarelli C, Sensi LG, Marcucci F, Cavagni G: Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000;55:1142–1147.
  35. Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML, Bruno ME, Falagiani P, Riva G: Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. Allergol Immunopathol 2006;34:194–198.
  36. Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I, Majani G, Falagiani P, Bruno M, Canonica GW: Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006;61:849–854.
  37. Gehlhar K, Rajashankar KR, Hofmann E, Betzel C, Weber W, Werner S, Bufe A: Lysine as a critical amino acid for IgE binding in Phl p 5b C terminus. Int Arch Allergy Immunol 2006;140:285–294.
  38. Stark GR: Reactions of cyanate with functional group of proteins; in Grossman L, Moldave K (eds): Methods in Enzymology. New York, Academic Press, 1972, vol 25, p 579.
  39. Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani P, Mistrello G, Canonica GW, Mariani G: Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001;31:54–60.
  40. Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Falagiani P, Canonica GW, Passalacqua G: Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 2005;138:197–202.
  41. Hendrix SG, Patterson R, Zeiss CR, Pruzansky JJ, Suszko IM, McQueen RC, Slavin RG, Miller MP, Lieberman PL, Sheffer AL: A multi-institutional trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol 1980;66:486–494.
  42. Grammer LC, Zeiss CR, Suszko IM, Shaughnessy MA, Patterson R: A double-blind, placebo-controlled trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol 1982;69:494–499.
  43. Bousquet J, Maasch HJ, Hejjaoui A, Skassa-Brociek W, Wahl R, Dhivert H, Michel FB: Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. 3. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989;84:546–556.
  44. Georgitis JW, Nickelsen JA, Wypych JI, Barde SA, Clayton WF, Reisman RE: Local intranasal immunotheraphy with high-dose polymerized ragweed extract. Int Arch Allergy Appl Immunol 1986;81:170–173.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50